Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB – Get Rating) shares crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.23 and traded as low as $0.08. Navidea Biopharmaceuticals shares last traded at $0.09, with a volume of 9,259,779 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals in a report on Tuesday. They set a “sell” rating for the company.
Navidea Biopharmaceuticals Stock Down 7.0 %
The firm’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.26. The firm has a market cap of $2.99 million, a P/E ratio of -0.16 and a beta of 1.36.
Hedge Funds Weigh In On Navidea Biopharmaceuticals
A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Renaissance Technologies LLC raised its position in Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB – Get Rating) by 264.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 238,133 shares of the biopharmaceutical company’s stock after acquiring an additional 172,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.74% of Navidea Biopharmaceuticals worth $62,000 as of its most recent SEC filing. 5.55% of the stock is owned by institutional investors and hedge funds.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.
- Get a free copy of the StockNews.com research report on Navidea Biopharmaceuticals (NAVB)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.